Skip to Content

News & Events

Access our recent and archived press releases. This section also provides a calendar of upcoming events and presentations.

Our Newsroom


Our investor relations portal provides access to our financial information, filings, investor presentations and stock information.

Investor Tools

Our Products

We develop high-potential molecules that have compelling safety and promising efficacy data and transform them into proprietary products that enable significant advances in patient care and outcomes.

Our Products

A Growing Portfolio of Products for Serious Diseases

VIVUS is dedicated to meeting the needs and improving quality of life of patients with serious medical conditions and life-limiting diseases.

PANCREAZE® (pancrelipase) delayed-release capsules
for Exocrine Pancreatic Insufficiency (EPI)

Exocrine pancreatic insufficiency (EPI) is a condition that results from a deficiency in the production and/or secretion of pancreatic enzymes and can lead to chronic diarrhea, significant weight loss and malnutrition. While there is no cure for EPI, PANCREAZE, a pancreatic enzyme replacement therapy, is an effective therapy for managing the disease.

Learn More About EPI Learn More About PANCREAZE

Latest Press Releases


Other Links & Resources

You are about to leave the VIVUS LLC website

Links to third-party websites on are provided solely for your convenience.

VIVUS LLC does not control the content contained on any third-party website linked from this website. Activities on third-party websites will be governed by the policies and terms of use of those third parties.